

**Interim Financial Statements (Un-audited)  
1<sup>st</sup> Quarter Ended  
March 31, 2014**



**Beximco Pharmaceuticals Limited**

**Beximco Pharmaceuticals Limited**  
**Statement of Financial Position (Un-audited)**  
**As at March 31, 2014**

		Taka '000	
	Notes	As at March 31, 2014	As at December 31, 2013
<b>ASSETS</b>			
<b>Non-Current Assets</b>			
Property, Plant and Equipment- Carrying Value	3	18,594,433	18,567,329
Intangible Assets		18,388,159	18,364,313
Investment in Shares		201,711	198,223
		4,563	4,793
<b>Current Assets</b>			
Inventories	4	9,086,318	8,903,422
Spares & Supplies		2,466,623	2,411,882
Accounts Receivable		438,665	433,352
Loans, Advances and Deposits	5	1,284,817	1,249,435
Short Term Investment		1,216,441	1,186,637
Cash and Cash Equivalents	6	3,545,796	3,026,383
		133,976	595,733
<b>TOTAL ASSETS</b>		<b>27,680,751</b>	<b>27,470,751</b>
<b>EQUITY AND LIABILITIES</b>			
<b>Shareholders' Equity</b>			
Issued Share Capital		20,067,496	19,775,552
Share Premium		3,503,349	3,503,349
Excess of Issue Price over Face Value of GDRs		5,269,475	5,269,475
Capital Reserve on Merger		1,689,637	1,689,637
Revaluation Surplus		294,951	294,951
Fair Value Gain on Investment		1,307,954	1,349,579
Retained Earnings		1,111	1,341
		8,001,019	7,667,220
<b>Non-Current Liabilities</b>			
Long Term Borrowings-Net off Current Maturity (Secured) 7 A		3,224,062	3,312,618
Liability for Gratuity and WPPF & Welfare Funds		1,002,600	1,151,401
Deferred Tax Liability		634,914	610,628
		1,586,548	1,550,589
<b>Current Liabilities and Provisions</b>			
Short Term Borrowings (Secured)		4,389,193	4,382,581
Long Term Borrowings-Current Maturity (Secured) 7 B		2,915,193	2,776,266
Creditors and Other Payables		744,747	754,904
Accrued Expenses		270,399	383,171
Dividend Payable		170,653	141,582
Income Tax Payable		889	973
		287,312	325,685
<b>TOTAL EQUITY AND LIABILITIES</b>		<b>27,680,751</b>	<b>27,470,751</b>

*Nazmul Hassan*

**Nazmul Hassan**  
 Managing Director

*Ali Nawaz*

**Ali Nawaz**  
 Chief Financial Officer

**Beximco Pharmaceuticals Limited**  
**Statement of Comprehensive Income (Un-audited)**  
**For the 1<sup>st</sup> Quarter Ended March 31, 2014**

		Taka '000	
	Notes	1st Quarter Ended March 31, 2014	1st Quarter Ended March 31, 2013
Net Sales Revenue		2,576,260	2,263,013
Cost of Goods Sold	8	<u>(1,439,165)</u>	<u>(1,264,382)</u>
<b>Gross Profit</b>		<b>1,137,095</b>	<b>998,631</b>
<b>Operating Expenses</b>		<b>(637,008)</b>	<b>(569,797)</b>
Administrative Expenses	9	<u>(103,801)</u>	<u>(91,550)</u>
Selling, Marketing and Distribution Expenses	10	<u>(533,207)</u>	<u>(478,247)</u>
<b>Profit from Operations</b>		<b>500,087</b>	<b>428,834</b>
Other Income	11	<u>100,396</u>	<u>122,443</u>
Finance Cost		<u>(175,360)</u>	<u>(148,645)</u>
<b>Profit Before Contribution to WPPF &amp; Welfare Funds</b>		<b>425,123</b>	<b>402,632</b>
Contribution to WPPF & Welfare Funds		<u>(20,244)</u>	<u>(19,173)</u>
<b>Profit Before Tax</b>		<b>404,879</b>	<b>383,459</b>
<b>Income Tax Expenses</b>		<b>(75,095)</b>	<b>(100,532)</b>
Current Tax		<u>(76,745)</u>	<u>(68,644)</u>
Deferred Tax		<u>1,650</u>	<u>(31,888)</u>
<b>Profit After Tax</b>		<b>329,784</b>	<b>282,927</b>
Other Comprehensive Income-			
Fair Value Loss on Investment in Listed Shares		<u>(230)</u>	<u>-</u>
<b>Total Comprehensive Income</b>		<b><u>329,554</u></b>	<b><u>282,927</u></b>

Earnings Per Share (EPS) / Adjusted EPS	Tk.	0.94	0.81
Number of Shares used to compute EPS		350,334,907	350,334,907

*Nazmul Hassan*

**Nazmul Hassan**  
 Managing Director

*Ali Nawaz*

**Ali Nawaz**  
 Chief Financial Officer

**Beximco Pharmaceuticals Limited**  
**Statement of Changes in Equity (Un-audited)**  
**For the 1<sup>st</sup> Quarter Ended March 31, 2014**

Taka '000

As at March 31, 2014								
	Share Capital	Share Premium	Excess of Issue Price over Face Value of GDRs	Capital Reserve on Merger	Revaluation Surplus	Fair Value Gain / (Loss) on Investment	Retained Earnings	Total
Balance as on January 01, 2014	3,503,349	5,269,475	1,689,637	294,951	1,349,579	1,341	7,667,220	19,775,552
Total Comprehensive Income for the period :								
Profit for the Period	—	—	—	—	—	—	329,784	329,784
Other Comprehensive Income / (Loss)	—	—	—	—	—	(230)	—	(230)
Adjustment for Depreciation on Revalued Assets	—	—	—	—	(4,015)	—	4,015	—
Adjustment for Deferred Tax on Revalued Assets	—	—	—	—	(37,610)	—	—	(37,610)
<b>Balance as on March 31, 2014</b>	<b>3,503,349</b>	<b>5,269,475</b>	<b>1,689,637</b>	<b>294,951</b>	<b>1,307,954</b>	<b>1,111</b>	<b>8,001,019</b>	<b>20,067,496</b>
Number of Shares on March 31, 2014							350,334,907	
Net Asset Value (NAV) Per Share on March 31, 2014							Tk. 57.28	

As at March 31, 2013								
	Share Capital	Share Premium	Excess of Issue Price over Face Value of GDRs	Capital Reserve on Merger	Revaluation Surplus	Fair Value Gain / (Loss) on Investment	Retained Earnings	Total
Balance as on January 01, 2013	3,046,390	5,269,475	1,689,637	294,951	1,406,528	—	6,701,181	18,408,162
Total Comprehensive Income for the period :								
Profit for the Period	—	—	—	—	—	—	282,927	282,927
Other Comprehensive Income / (Loss)	—	—	—	—	—	—	—	—
Adjustment for Depreciation on Revalued Assets	—	—	—	—	(4,559)	—	4,559	—
Adjustment for Deferred Tax on Revalued Assets	—	—	—	—	(38,228)	—	—	(38,228)
<b>Balance as on March 31, 2013</b>	<b>3,046,390</b>	<b>5,269,475</b>	<b>1,689,637</b>	<b>294,951</b>	<b>1,363,741</b>	<b>—</b>	<b>6,988,667</b>	<b>18,652,861</b>
Number of Shares on March 31, 2013							304,639,050	
Net Asset Value (NAV) Per Share on March 31, 2013							Tk. 61.23	

*Nazmul Hassan*

Nazmul Hassan  
Managing Director

*Ali Nawaz*

Ali Nawaz  
Chief Financial Officer

**Beximco Pharmaceuticals Limited**  
**Statement of Cash Flows (Un-audited)**  
**For the 1<sup>st</sup> Quarter Ended March 31, 2014**

	Taka '000									
	1st Quarter Ended March 31, 2014	1st Quarter Ended March 31, 2013								
<b>Cash Flows from Operating Activities :</b>										
Receipts from Customers and Others	2,540,964	2,228,154								
Payments to Suppliers and Employees	(2,054,259)	(1,935,379)								
<b>Cash Generated from Operations</b>	<b>486,705</b>	<b>292,775</b>								
Interest Paid	(175,360)	(148,645)								
Interest Received	99,311	122,611								
Income Tax Paid	(115,118)	(36,491)								
<b>Net Cash Generated from Operating Activities</b>	<b>295,538</b>	<b>230,250</b>								
<b>Cash Flows from Investing Activities :</b>										
Acquisition of Property, Plant and Equipment	(212,106)	(69,717)								
Intangible Assets	(7,265)	(16,010)								
Disposal of Property, Plant and Equipment	604	60								
Short Term Investment	(519,413)	(123,724)								
<b>Net Cash Used in Investing Activities</b>	<b>(738,180)</b>	<b>(209,391)</b>								
<b>Cash Flows from Financing Activities :</b>										
Net Decrease in Long Term Borrowings	(158,958)	(43,362)								
Net Increase in Short Term Borrowings	139,927	38,923								
Dividend Paid	(84)	(9)								
<b>Net Cash Generated from Financing Activities</b>	<b>(19,115)</b>	<b>(4,448)</b>								
<b>Increase / (Decrease) in Cash and Cash Equivalents</b>	<b>(461,757)</b>	<b>16,411</b>								
Cash and Cash Equivalents at Beginning of Period	595,733	552,979								
<b>Cash and Cash Equivalents at End of Period</b>	<b>133,976</b>	<b>569,390</b>								
<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%;"><b>Net Operating Cash Flow Per Share</b></td> <td style="text-align: center; width: 10%;">Tk.</td> <td style="text-align: right; width: 20%;">0.84</td> <td style="text-align: right; width: 20%;">0.76</td> </tr> <tr> <td><b>Number of Shares used to compute Net Operating Cash Flow Per Share</b></td> <td></td> <td style="text-align: right;">350,334,907</td> <td style="text-align: right;">304,639,050</td> </tr> </table>			<b>Net Operating Cash Flow Per Share</b>	Tk.	0.84	0.76	<b>Number of Shares used to compute Net Operating Cash Flow Per Share</b>		350,334,907	304,639,050
<b>Net Operating Cash Flow Per Share</b>	Tk.	0.84	0.76							
<b>Number of Shares used to compute Net Operating Cash Flow Per Share</b>		350,334,907	304,639,050							

*Nazmul Hassan*

**Nazmul Hassan**  
Managing Director

*Ali Nawaz*

**Ali Nawaz**  
Chief Financial Officer

**Beximco Pharmaceuticals Limited**  
**Selected Notes to the Financial Statements (Un-audited)**  
**For the 1<sup>st</sup> Quarter Ended March 31, 2014**

**1. Reporting Entity**

Beximco Pharmaceuticals Limited (BPL/the Company) is a public company incorporated in Bangladesh in 1976. It commenced its manufacturing operation in 1980. The company is listed on Dhaka and Chittagong Stock Exchanges of Bangladesh and AIM of London Stock Exchange. The company is engaged in manufacturing and marketing of Pharmaceuticals Finished Formulation Products, Active Pharmaceutical Ingredients (APIs) and life saving Intravenous Fluids which it sells in the local as well as international markets.

**2. Basis of Preparation of Financial Statements**

These interim financial statements should be read in conjunction with the Financial Statements for the year ended December 31, 2013 (hereafter referred to as the "Annual Financial Statements"), as they provide an update to previously reported information.

The accounting policies used are consistent with those used in the Annual Financial Statements. The financial statements have been prepared in accordance with the International Financial Reporting Standards (IFRSs). The presentation of the Interim Financial Statements is consistent with the Annual Financial Statements. Where necessary, the comparatives have been reclassified or extended to take into account any presentational changes made in the Annual Financial Statements. The preparation of the Interim Financial Statements requires management to make estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities at the date of the Interim Financial Statements. If in the future such estimates and assumptions, which are based on management's best judgment at the date of the Interim Financial Statements, deviate from the actual, the original estimates and assumptions will be modified as appropriate in the period in which the circumstances change.

Taka '000

	<b>As at March 31, 2014</b>	<b>As at December 31, 2013</b>
--	---------------------------------	------------------------------------

**3. Property, Plant & Equipment**

Land	3,302,883	3,302,883
Building and Other Constructions	6,370,759	6,370,759
Plant and Machinery	10,084,354	10,034,644
Furniture and Fixture	176,708	173,334
Transport and Vehicle	552,768	548,077
Office Equipment	370,241	358,363
	<b>20,857,713</b>	<b>20,788,060</b>
Less :Accumulated Depreciation	(4,873,320)	(4,686,815)
<b>Net Book Value</b>	<b>15,984,393</b>	<b>16,101,245</b>
Capital Work in Progress	2,403,766	2,263,068
<b>Carrying Value</b>	<b><u>18,388,159</u></b>	<b><u>18,364,313</u></b>

Taka '000

	<b>As at March 31, 2014</b>	<b>As at December 31, 2013</b>
<b>4. Inventories</b>		
Finished Goods	634,568	644,006
Raw and Packing Materials (Including Work in Process and Transit)	1,729,497	1,675,642
Physician Sample	102,558	92,234
	<u><b>2,466,623</b></u>	<u><b>2,411,882</b></u>
<b>5. Loans, Advances and Deposits</b>		
Clearing & Forwarding	33,647	43,789
VAT	216,631	224,272
Security Deposit and Earnest Money	16,948	21,814
Capital Expenditure / Project	39,234	39,234
Advance against Salary	49,842	51,306
Motor Cycle	147,274	156,329
Raw & Packing Material	410,990	409,578
Overseas Liaison Office	9,969	9,969
Others	291,906	230,346
	<u><b>1,216,441</b></u>	<u><b>1,186,637</b></u>
<b>6. Cash and Cash Equivalents</b>		
(a) Cash in Hand (Including Imprest Cash)	2,336	3,475
(b) Cash at Bank:		
(i) Current and FC Account	104,947	85,680
(ii) FDR Account	26,693	506,578
	<u><b>133,976</b></u>	<u><b>595,733</b></u>
<b>7. Long Term Borrowings</b>		
<b>A. Net off Current Maturity (Secured)</b>		
Project Loan	866,725	1,001,325
Obligation Under Finance leases	135,875	150,076
	<u><b>1,002,600</b></u>	<u><b>1,151,401</b></u>
<b>B. Current Maturity (Secured)</b>		
Project Loan	652,919	652,690
Obligation Under Finance leases	91,828	102,214
	<u><b>744,747</b></u>	<u><b>754,904</b></u>

Taka '000

	<b>1st Quarter Ended March 31, 2014</b>	<b>1st Quarter Ended March 31, 2013</b>
<b>8. Cost of Goods Sold</b>		
Materials	1,024,132	933,517
Factory Overhead	246,246	210,028
Depreciation	168,787	120,837
	<u>1,439,165</u>	<u>1,264,382</u>
<b>9. Administrative Expenses</b>		
Salary & Allowances	45,548	42,702
Repairs & Maintenance	7,558	5,742
Travelling & Conveyance	4,708	4,396
AGM, Company Secretarial and Regulatory Expense	7,006	8,846
Depreciation	6,528	4,673
Other Expenses	32,453	25,191
	<u>103,801</u>	<u>91,550</u>
<b>10. Selling, Marketing and Distribution Expenses</b>		
Salary & Allowances	176,906	151,913
Travelling & Conveyance	73,548	68,979
Market Research & New Products	7,536	8,403
Sample, Literature & Promotional Expenses	150,139	133,141
Delivery Expense	65,092	61,070
Depreciation and Amortization	14,967	11,543
Other Expenses	45,019	43,198
	<u>533,207</u>	<u>478,247</u>

**11. Other Income**


This includes gain of Taka 1,000,000 (Taka one million) arising from conversion of foreign currency loan at prevailing exchange rate on the date of Statement of Financial Position.

**12. Proposed Dividend for 2013**

The Board of Directors of the Company in its meeting held on 29 April, 2014 has proposed 10% cash and 5% stock dividend for the year 2013 which is subject to approval in the annual general meeting to be held on June 21, 2014. The company consistently follows the policy of recognising proposed dividend after its approval by the shareholders in the annual general meeting. Hence proposed dividend for 2013 has not been accounted for in this interim financial statements.



**Nazmul Hassan**  
Managing Director



**Ali Nawaz**  
Chief Financial Officer